Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the relations between anaplastic lymphoma kinase (<i>ALK</i>) and v-myc myelocytomatosis viral related oncogene neuroblastoma derived homolog (<i>MYCN</i>) protein expression and their prognostic roles in neuroblastoma tumours.
|
31542727 |
2020 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since most cases are in children under the age of 2, understanding the role and regulation of ALK during neural crest development is an important goal in addressing neuroblastoma tumorigenesis.
|
30803032 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data confirm that PIM1 overexpression decreases sensitivity to ALK inhibitors in NB, and suggests that combined front-line inhibition of ALK and PIM1 is a viable strategy for the treatment of ALK-positive NB independent of MYCN status.
|
31780656 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK-amplified NBs were correlated with synchronous MYCN amplification and chromosome 1p deletion.
|
28326957 |
2019 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Studies have shown that native ALK protein is expressed on the surface of most neuroblastoma cells, providing an opportunity for development of immune-targeting strategies.
|
30867324 |
2019 |
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Altogether, this study provides novel insights into ALK mutation dynamics in a neuroblastoma model harbouring two ALK mutations.
|
31452835 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The agent targets ALK, which is found on neuroblastoma cells but not healthy cells, delivering a drug that causes DNA cross-links.
|
31043380 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple therapeutic approaches are being used to target MYCN, ALK, and TrkB, as well as GD2, a surface antigen present on the surface of neuroblastoma tumor cells.
|
31092383 |
2019 |
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Three hotspot residues (F1174, F1245, and R1275) account for 85% of mutant ALK seen in neuroblastoma.
|
30778092 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results suggest that alectinib is an effective inhibitor of ALK kinase activity in ALK addicted neuroblastoma and should be considered as a potential future therapeutic option for ALK-positive neuroblastoma patients alone or in combination with other treatments.
|
31334113 |
2019 |
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the Anaplastic lymphoma tyrosine kinase (ALK) gene are common in NB.
|
30605844 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Resistance to ALK Inhibitors in Neuroblastoma Is Regulated by BORIS.
|
31420353 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Through a case study of mutations in kinase domains of three proteins, namely, the anaplastic lymphoma kinase (ALK) in pediatric neuroblastoma patients, serine/threonine-protein kinase B-Raf (BRAF) in melanoma patients, and erythroblastic oncogene B 2 (ErbB2 or HER2) in breast cancer patients, we compare the two approaches above.
|
30982079 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanisms of acquired resistance to ALK inhibition therapy in neuroblastoma have not yet been elucidated.
|
31614113 |
2019 |
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although expression of ALK F1174L resulted in enhanced proliferation of sympathetic ganglion progenitors and increased the size of the sympathetic ganglia, it was insufficient to cause neuroblastoma.
|
31218818 |
2019 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ALK overexpression and activation, in the absence of genetic mutation has also been described in NB.
|
31340081 |
2019 |
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combined treatment with alectinib and vorinostat might be a novel therapeutic option for NB harboring the ALK R1275Q mutation.
|
31262882 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Anaplastic Lymphoma Kinase (<i>ALK</i>) gene is frequently altered in NB, through copy number alterations and activating mutations, and represents a predisposition in NB-genesis when mutated.
|
31058082 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We review the basic aspects of MYCN, Trk, and ALK in both neural development and in neuroblastoma.
|
30848386 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we established both phosphoproteomic and gene expression profiles of ALK activity in neuroblastoma cells exposed to first- and third-generation ALK TKIs, to identify the underlying molecular mechanisms and identify relevant biomarkers, signaling networks, and new therapeutic targets.
|
30459281 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bioinformatic analyses revealed that the mRNA expression level of HDAC8 was significantly correlated with that of ALK in two independent patient cohorts, the Academic Medical Center cohort (n = 88) and the German Neuroblastoma Trial cohort (n = 649), and co-expression of both target genes identified patients with very poor outcome.
|
29515255 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase (ALK) gene activation is involved in the carcinogenesis process of several human cancers such as anaplastic large cell lymphoma, lung cancer, inflammatory myofibroblastic tumors and neuroblastoma, as a consequence of fusion with other oncogenes (NPM, EML4, TIM, etc) or gene amplification, mutation or protein overexpression.
|
29455642 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, truncated ALK protein was also reported in neuroblastoma.
|
28665006 |
2018 |
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Alterations in anaplastic lymphoma kinase (<i>ALK</i>) gene are involved in neuroblastoma, lung cancer, and other malignancies, but its role in SCCP has not been documented.
|
29559559 |
2018 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate that ETV5 is regulated both at the protein and mRNA levels upon ALK activation or inhibition in neuroblastoma cell lines and that this regulation precedes RET modulation.
|
29321660 |
2018 |